BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
NCT07570394
Summary
As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety profile of Breztri in real-world clinical practice settings, either confirming known safety outcomes or identifying previously unsuspected adverse drug reactions. The study will also evaluate effectiveness of Breztri in real-world clinical practice settings, generating essential clinical evidence from a broader and more diverse Korean patient population representative of daily medical practice.
Eligibility
Inclusion Criteria: 1. Patients who have been diagnosed with COPD or asthma. 2. Patients who have newly initiated treatment with Breztri according to the approved label in Korea 3. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: 1. Other off-label indications outside of the locally approved prescribing information 2. Pregnant and/or breast feeding 3. Current participation in any interventional trial
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07570394